Business Wire

The Mary Kay FoundationSM and UT Southwestern Partner to End Cancers Impacting Women Globally

Share

The Mary Kay FoundationSM, a decades-long leader in the charge to eliminate cancers affecting women, recently announced a $500,000 grant to fund a groundbreaking global fellowship program with long-time partner UT Southwestern Medical Center. The new one-year fellowships will offer up to five international postdoctoral researchers the opportunity to conduct cutting-edge cancer research at the world-renowned UT Southwestern facility in Dallas, and allow them to continue research activity in their native country. This new grant program supports The Mary Kay Foundation’s continued commitment to ending women-related cancers around the world and marks the first time the Foundation’s cancer research grants program goes global.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190828005139/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Mary Kay Foundation℠ has a long-standing partnership with UT Southwestern through a strong collaboration with Dr. Jerry W. Shay, cell biology professor at UT Southwestern and The Mary Kay Foundation℠ Distinguished Professorship honoree. (Photo: Mary Kay Inc.)

“Mary Kay Ash, our founder, saw firsthand the impact that cancer had on our independent beauty consultants, their families, and women around the world,” said Ryan Rogers, board member of The Mary Kay FoundationSM and grandson of Mary Kay Ash. “It became a mission for her to eradicate cancers affecting women. Our expanded partnership with UT Southwestern will allow us to continue that lifesaving work on a global scale.”

The Mary Kay FoundationSM has a long-standing partnership with UT Southwestern through a strong collaboration with Dr. Jerry W. Shay, cell biology professor at UT Southwestern and The Mary Kay FoundationSM Distinguished Professorship honoree. Dr. Shay has served as chair of the scientific review committee for The Mary Kay Foundation Innovative/Translational Cancer Research Grant Program in the U.S. for the last 22 years and will now serve as principal investigator over the new international fellowship program.

“Expanding the program internationally will allow us to focus on cancers that affect women the most,” said Dr. Shay. “We plan to identify a group of dedicated postdoctoral candidates from around the globe, invite them to Dallas, and equip them with all the tools and resources they need to continue their groundbreaking research in our outstanding cancer lab. Their work could have a tremendous impact on how we understand and treat cancers around the world.”

Since its establishment in 1996, The Mary Kay FoundationSM has supported Mary Kay Ash’s dedication to advocating on behalf of women and her vision of creating a cancer-free world. To date, The Mary Kay FoundationSM has awarded nearly $23 million to support the work of 225 top women-related cancer researchers across the U.S., funding efforts to search for cures for breast, uterine, cervical and ovarian cancers.

“Fighting cancer was personal for Mary Kay Ash,” said Dr. Gildea, Chief Scientific Officer at Mary Kay Inc. “And it’s personal to us. She would have been proud that we’re continuing her legacy of serving women on an even larger scale.”

About The Mary Kay Foundation℠

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, The Mary Kay FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers, and ending domestic violence against women. Since 1996, The Mary Kay FoundationSM has contributed more than $78 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayfoundation.org, find us on Facebook and Instagram, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The Mary Kay Foundation
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 10:00:00 EEST | Press release

Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from broadband connectivity, diagnostics to eventually supporting autonomous driving capabilities.” The successful test focused on a commercial land mobile use case

Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 10:00:00 EEST | Press release

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 09:14:00 EEST | Press release

GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s dat

Reply Presents “App to the Future”: A New AI-Scape Room Experience Powered by Microsoft AI and Low-Code Solutions14.5.2025 09:05:00 EEST | Press release

Reply, a global systems integrator and technology consulting firm, introduces “App to the Future” an immersive “AI-Scape Room” an immersive escape room experience powered by Microsoft Copilot, Azure AI, and Power Platform, designed to explore the full potential of AI and low-code tools in a unique and engaging way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513072546/en/ The experience builds on Reply’s AI-Scape Room focused on Microsoft 365 Copilot, offering enhanced challenges and deeper integration of advanced AI tools to help participants better understand how these technologies can drive business transformation. Developed by WM Reply and Valorem Reply, the Reply companies specialised in digital workplace transformation and AI solutions, “App to the Future” invites participants to engage in an interactive experience where they tackle AI-powered challenges using Microsoft’s suite of tools - including Copilot, Azure

Svante Launches World's First Commercial Gigafactory for Carbon Capture & Removal Filters13.5.2025 23:50:00 EEST | Press release

Svante Technologies Inc. (Svante), a global leader in carbon capture and removal technologies, has officially completed the commissioning of its new Centre of Excellence for Carbon Capture and Removal – Redwood manufacturing Facility (Redwood) in Burnaby, British Columbia. This milestone marks the launch of the world's first gigafactory dedicated to producing commercial-scale carbon capture and removal filters designed to trap CO2 directly from industrial emissions and the atmosphere, and with the mindset of high-volume automation and product standardization to lower the manufacturing cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513713072/en/ Claude Letourneau, President & CEO, Svante Group opens the Svante Grand Opening 2025 event, "GO25" with a speech about how to move the carbon management industry forward. This two-day event celebrates the commissioning of Svante's gigafactory in Vancouver, BC, Canada, which w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye